30 January 2019 - The Global Diabetes
Injection Pens Market is estimated to rise at a significant rate in the
coming years owing to rising applications and scope around the world. Diabetes
injection pen is an instrument that is employed to insert insulin and deliver
the dose while carrying out the treatment of diabetes. An insulin cartridge is
incorporated in the device and a dial is there that is deployed to assess the
dose level.
The
most striking features that are attached with the usage of diabetes injection
pens may include simplified design and structure, precision, handiness, and
compact size. It is available in wide varieties. It has been observed that
initiation of insulin pens and advancement in the product due to emerging
technology is having an optimistic impact on the Diabetes Injection Pens
markets growth. The manufacturers are developing the product with various
advanced features so that burgeoning requirements of the end users can be met.
The
factors that are responsible for raising the Diabetes Injection Pens market
share may include industrialization, urbanization, technological advancements,
rise in the demands among the end users, growing prerequisites of regular
insulin management, rise in the occurrence of diabetes, increase in the number
of patients, and augmentation in the investments by the government authorities
in the healthcare sector.
Moreover,
factors such as rising users of insulin injections and rise in the frequency of
needle stick injury among the population are contributing simultaneously in the
Diabetes Injection Pens markets growth. Diabetes Injection Pens Industry is
categorized as diabetes type by Type I, Type II diabetes, and others.
Diabetes
Injection Pens Market is segregated by product type as Insulin Pens, Insulin
Pen Needles, and others. As far as the product types are concerned, the segment
of Insulin Pens covers the largest share as compared to other segments.
Diabetes Injection Pens Market is divided on the basis of usage as Reusable,
Disposable, and others. Among all the forms, it has been noticed that the
segment of Reusable is taking up a considerable share in the market.
Diabetes
Injection Pens Market is segmented by distribution channels as Retail Pharmacy,
Online Sales, Hospital Pharmacy, Diabetes Centres, and others. As far as the
distribution channel goes, the segment of Hospital Pharmacy is currently
holding a significant share in the overall market. The industry is classified
by geography as North America, Europe, China, Japan, Southeast Asia, and India.
Among
all the geographical regions, it has been North America is lately been
considered as the leading region in the market and it is simultaneously
accounting for the largest share in the market, the reason being rise in the
availability of various reimbursements for the diabetes management, huge
occurrence of diabetes, and augmented awareness among the end users regarding
the efficiency of the product. The United States is the major contributor in
the particular regions market growth.
On
the contrary, Asia Pacific is also emerging as one of the promising regions in
the market. The factors that can be attributed to the robust growth may entail
rising awareness among the masses, rise in the expenditure by the government
authorities in the healthcare sector, and growth of the healthcare
infrastructure.
The
prominent players that are contributing in the development of the Diabetes
Injection Pens Market are recognized as Biocon Ltd., Owen Mumford Ltd.,
Wockhardt Ltd, AstraZeneca plc, Becton, and Jiangsu Delfu Co.
Market Segment:
Geographically, this report is segmented
into several key Regions, with production, consumption, revenue (million USD),
market share and growth rate of Diabetes Injection Pens in these regions, from
2013 to 2025 (forecast), covering
•
North America
•
Europe
•
China
•
Japan
•
Southeast Asia
•
India
Global Diabetes Injection Pens market
competition by top manufacturers, with production, price, revenue (value) and
market share for each manufacturer; the top players including
•
Novo Nordisk A/S
•
Eli Lilly and Company
•
AstraZeneca plc
•
Biocon Ltd.
•
Sanofi S.A.
•
Becton, Dickinson and Company
•
Owen Mumford Ltd.
•
Jiangsu Delfu Co., Ltd.
•
Wockhardt Ltd.
Comments
Post a Comment